Scinai Immunotherapeutics (SCNI) Total Non-Current Liabilities (2016 - 2026)

Scinai Immunotherapeutics has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $3.2 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 72.45% year-over-year to $3.2 million; the TTM figure through Jun 2026 stood at $3.2 million (up 72.45% YoY), while the FY2025 annual figure was $1.9 million, up 16.4% from the prior year.
• Total Non-Current Liabilities came in at $3.2 million for Q2 2026 at Scinai Immunotherapeutics, up from $3.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $26.5 million in Q4 2022 to a low of $866000.0 in Q3 2024.
• Average Total Non-Current Liabilities over 5 years is $13.6 million, with a median of $17.0 million recorded in 2022.
• Year-over-year, Total Non-Current Liabilities surged 1549.52% in 2022 and sank 95.61% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $26.5 million in 2022, then decreased by 23.51% to $20.3 million in 2023, then plunged by 91.78% to $1.7 million in 2024, then increased by 16.4% to $1.9 million in 2025, then surged by 65.69% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $3.2 million in Q2 2026, $3.1 million in Q1 2026, and $1.9 million in Q4 2025.